A consistent progression-free and overall survival benefit was reported among patients with hormone receptor-positive, HER2-negative advanced breast cancer, regardless of age.
Russ Conroy
Advertisement
Russ Conroy is an Assistant Editor for CancerNetwork. He grew up in Hillsborough, New Jersey, and graduated from Rutgers University-New Brunswick in 2022.
On the weekends, he likes to unwind by playing video games with friends, tailgating at Rutgers football games with his family, or building his music collection with a visit to Princeton Record Exchange.
Articles by Russ Conroy
Patients treated with mRNA-4157 plus pembrolizumab experienced an approximately 44% reduction in the risk of death or recurrence compared to those receiving pembrolizumab alone.
Final overall survival analysis highlights benefit of lenvatinib plus pembrolizumab vs sunitinib in the treatment of patients with advanced renal cell carcinoma.
Adjuvant pembrolizumab improved disease-free survival outcomes vs placebo across subgroups of patients with clear cell renal cell carcinoma in the KEYNOTE-564 study.
Maintenance bevacizumab plus durvalumab and olaparib improved progression-free survival in patients with HRD-negative advanced ovarian cancer.
Nivolumab/Cabozantinib continued to outperform sunitinib in an updated analysis of the phase 3 CheckMate 9ER trial.
Advertisement
Advertisement
Advertisement
